# Cancer Immunotherapy Winter School (CIWS)

> **NIH NIH R13** · SOCIETY FOR IMMUNOTHERAPY OF CANCER, INC. · 2022 · $30,000

## Abstract

4.0 PROJECT SUMMARY/ABSTRACT
Established in 1984, the Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven
organization specifically dedicated to improving cancer patient outcomes by advancing the science and
application of cancer immunotherapy. The mission of SITC is to improve cancer patient outcomes by
advancing the science, development and application of cancer immunology and immunotherapy through our
core values of interaction/integration, innovation, translation and leadership in the field. At the forefront of
SITC’s educational charge is the Cancer Immunotherapy Winter School (CIWS) program. The 2022 program in
Austin, TX will focus on delivering a program designed to enable basic, clinical, or translational scientists and
clinicians from the entire cancer care team including those from diverse and underrepresented groups in
biomedical sciences, to advance scientific discoveries and clinical applications of tumor immunology and
cancer immunotherapy. This comprehensive, five-day accredited CME-/CNE-/CPE-/MOC-certified program will
provide a deep understanding of the core principles of tumor immunology, cancer immunotherapy and
developing areas in the field. With 51 topics including foundational immunology, clinical trial design,
combination therapies, biomarker integration and data analysis, attendees have a number of session types (all-
attendee, breakout, research/clinical tracks) tailored to maximize learning opportunities and styles through
selection of sessions most relevant to their educational needs. This allows for many opportunities of
personalized interaction between attendees and experts. Attendees, through small group sessions and
networking roundtables, will expand their professional network, developing new relationships with faculty and
other thought leaders. These hands-on sessions will provide valuable networking and mentorship
opportunities, and poise questions from their own experiences. Designed and approved by experts across the
healthcare spectrum—clinical physicians, nurses, pharmacists, emergency physicians, and patient
advocates—establishes that all points of view are incorporated. For attendees of in-person courses, enduring
materials are available following the program and will serve as reinforcement of their learnings and allow
access to other concurrent sessions they could not attend. Materials are available to the public six months later
at a nominal fee. SITC, program organizers, and faculty certifies the CIWS is open to all who wish to attend
and it is a safe and respectful learning environment free from all forms of discrimination and harassment. Low
registration rates, travel awards, ADA-compliant facilities, and a centralized location ensures that obstacles do
not stand in the way of physicians’ knowledge and eventual use of these revolutionary treatments. SITC is
uniquely poised to hold this premier, educational option for all healthcare professionals and every type of
learner. N...

## Key facts

- **NIH application ID:** 10391811
- **Project number:** 1R13CA268648-01
- **Recipient organization:** SOCIETY FOR IMMUNOTHERAPY OF CANCER, INC.
- **Principal Investigator:** Catherine M. Bollard
- **Activity code:** R13 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $30,000
- **Award type:** 1
- **Project period:** 2022-01-01 → 2022-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10391811

## Citation

> US National Institutes of Health, RePORTER application 10391811, Cancer Immunotherapy Winter School (CIWS) (1R13CA268648-01). Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/grant/nih/10391811. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*